Concord Repatriation General Hospital
Australia
- Country
- Australia
- Ownership
- Private
- Established
- 1942-01-01
- Employees
- -
- Market Cap
- -
World-First Clinical Trial: LIGŌ 3D Bioprinting Device Revolutionizes Wound Treatment Using Patient's Own Cells
• Australian biotechnology company Inventia Life Science has launched the world's first clinical trial of LIGŌ, a 3D bioprinting device that delivers patients' own cells directly to wound sites without requiring skin grafts.
• The LIGŌ device works like an inkjet printer, precisely depositing nano-sized droplets of bioink containing living cells and biomaterials to create a scaffold that supports natural skin regeneration.
• Future applications may extend beyond burn treatment to include skin cancer excisions, diabetic ulcers, and potentially regeneration of muscle, cartilage, and cornea tissue, promising reduced hospital stays and healthcare costs.
© Copyright 2025. All Rights Reserved by MedPath